GlassScriptPhysician profile
Shyam Verma
NPI 1538358429
$1,960.77
in general payments reported to CMS, 2019-2025
18 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.41 · 2020: $121 · 2021: $20.85 · 2022: $41.72 · 2023: $572 · 2024: $656 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,662 · Education: $41.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.60 |
| Education | $41.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $532.82 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $350.67 | 2020-2025 | Jynarque |
| Amgen INC. | $209.16 | 2022-2025 | Krystexxa, Tavneos, Repatha |
| Astrazeneca Pharmaceuticals LP | $170.48 | 2019-2025 | Farxiga |
| Mallinckrodt Hospital Products INC. | $165.25 | 2023-2025 | Acthar, Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.06 | 2023-2025 | Jardiance |
| Horizon Therapeutics Plc | $67.60 | 2023 | Krystexxa |
| Veloxis Pharmaceuticals, INC. | $53.93 | 2019 | |
| Travere Therapeutics, INC. | $53.34 | 2025 | Filspari |
| Medtronic, INC. | $31.31 | 2023 | Ellipsys Vascular Access System |
| Glaxosmithkline, LLC. | $29.02 | 2023 | Benlysta |
| Alnylam Pharmaceuticals INC. | $24.78 | 2025 | Oxlumo |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Calliditas Therapeutics US INC. | $23.78 | 2023 | Tarpeyo |
| Lilly USA, LLC | $20.85 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $18.85 | 2024 | Ibsrela |
| Ani Pharmaceuticals, INC. | $14.66 | 2024 | Purified Cortrophin Gel |
| Novo Nordisk INC | $13.60 | 2025 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shyam Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.